Empagliflozin in Patients with Chronic Kidney Disease

BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. CONCLUSIONS: Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.
• 2 METHODS: , a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.
• 3 RESULTS: A total of 6609 patients underwent randomization.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: